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Abstract 
Background and purpose. The cyclopentapeptide FC131 (cyclo(-L-Arg1-L-Arg2-L-
2-Nal3-Gly4-D-Tyr5-)) is an antagonist for CXC-chemokine receptor 4 (CXCR4), 
which plays a role in HIV-infection, cancer and stem cell recruitment. Binding modes 
for FC131 in CXCR4 have previously been suggested based on molecular docking 
guided by structure-activity relationship (SAR) data; however, none of these have 
been verified by in vitro experiments.  
Experimental approach. Heterologous 125I-12G5-competition binding and functional 
assays (inhibition of CXCL12-mediated activation) of FC131 and three analogues 
were performed on WT CXCR4 and 25 receptor mutants. Computational modelling 
was used to rationalize the experimental data. 
Key results. The Arg2 and 2-Nal3 side chains of FC131 interact with residues in TM-
3 (His113, Asp171) and TM-5 (hydrophobic pocket), respectively. Arg1 forms charge-
charge interactions with Asp187 in ECL-2, while D-Tyr5 points to the extracellular side 
of CXCR4. Furthermore, the backbone of FC131 interacts with the chemokine 
receptor-conserved Glu288 via two water molecules. Intriguingly, Tyr116 and Glu288 
form a H-bond in CXCR4 crystal structures and mutation of either residue to Ala 
abolishes CXCR4 activity. 
Conclusions and implications. Ligand modification, receptor mutagenesis and 
computational modelling approaches were used to identify the binding mode of 
FC131 in CXCR4, which was in agreement with binding modes suggested from 
previous SAR studies. Furthermore, insights into the mechanism for CXCR4 
	   3	  
activation by CXCL12 were gained. The combined findings will facilitate future 
design of novel CXCR4 antagonists.  
Keywords. CXCR4, FC131, binding mode, receptor mutagenesis, SAR  
Abbreviations. 2-Nal, 3-(2-naphthyl)alanine; 7TM, 7 transmembrane helix; Aib, 2-
aminoisobutyric acid; Cit, citrulline; CXCR4, CXC-chemokine receptor 4; G-CSF, 
granulocyte colony-stimulating factor; HIV, human immunodeficiency virus; SAR, 
structure-activity relationship; WT, wildtype 
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Introduction 
 
The chemokine receptor CXCR4 belongs to class A 7 transmembrane helix (7TM) 
receptors, also known as G protein-coupled receptors (GPCRs). It plays a role in HIV 
infection by being a cell-entry co-factor for T-cell tropic HIV strains (Feng, 1996; 
Berson, 1996) and is together with its endogenous agonist CXCL12 central for stem 
cell recruitment and cancer development, progression and metastasis (Murphy, 2000; 
Balkwill, 2004; Bachelerie, 2014). These implications have facilitated the 
development of drug candidates targeting CXCR4 (Choi, 2012). One of these, the 
bicyclam compound AMD3100 (plerixafor), was approved in 2008 for hematopoietic 
stem cell mobilization in patients with multiple myeloma and non-Hodgkin´s 
lymphoma (DiPersio, 2009a; DiPersio, 2009b; Micallef, 2009), although the initial 
indication was as an anti-HIV compound (De Clercq, 1994; Steen, 2009).  
The polyphemusin II-derived peptides are a large class of CXCR4 antagonists that 
include the 14-mer T140 (Tamamura, 1998) and analogues, e.g. CVX15 (Wu, 2010), 
as well as the cyclic pentapeptide FC131 (Figure 1A) and analogues (Fujii, 2003). 
The cyclopentapeptide CXCR4 antagonists were designed by combining the four 
most important residues of T140 (Arg2, 2-Nal3, D-Tyr5, and Arg14) with a Gly residue 
to give a cyclopentapeptide library (Tamamura, 2000; Fujii, 2003). The optimal 
combination of sequence and stereochemistry was shown to be cyclo(-L-Arg1-L-Arg2-
L-2-Nal3-Gly4-D-Tyr5-), i.e. FC131, which displays nanomolar affinity and potency at 
CXCR4 (Fujii, 2003) and serves as lead compound for development of more drug-like 
peptidomimetic CXCR4 antagonists. SAR studies of FC131 have shown that although 
a positive charge is preferred at position 1, substitution of Arg1 with the uncharged 
citrulline (Cit), or even less structurally related amino acids, is tolerated (Tamamura, 
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2005a; Demmer, 2011; Mungalpara 2012). In contrast, Arg2 is a crucial functionality 
and minor modifications abolish activity (Tamamura, 2005b; Demmer, 2011; 
Mungalpara 2012). The aromatic residues in position 3 (2-Nal3) and 5 (D-Tyr5) are 
also important for proper function; importantly, position 3 requires conservation as 2-
Nal (Tamamura, 2005b; Mungalpara, 2013) while position 5 allows for some 
modifications (Tamamura, 2005b; Tanaka, 2009; Mungalpara, 2013). 
Several computational models for binding of peptide antagonists to CXCR4 have 
been suggested. The first models for T140 (Trent, 2003) and FC131 (Våbenø, 2006a; 
Kawatkar, 2011) were based on the crystal structure of bovine rhodopsin (Palczewski, 
2000); however, the subsequent publication of the crystal structures of CXCR4 (Wu, 
2010) revealed significant structural differences between rhodopsin and CXCR4. The 
co-crystal complex between CXCR4 and CVX15, a 16-mer analogue of T140, also 
showed that peptide CXCR4 antagonists bind differently than previously suggested. 
Based on molecular docking to this crystal structure, guided by SAR data, more 
reliable binding models have since emerged for the cyclopentapeptide antagonists 
(Demmer, 2011; Yoshikawa, 2012; Kobayashi, 2012; Mungalpara, 2012; 
Mungalpara, 2013). These models collectively suggest an interaction between Arg1 of 
FC131 and Asp187 (in ECL-2) and Asp97 in TM-2, while Arg2 interacts with His113 
(TM-3) and Asp171 (TM-4). (The position of residues according to the 
Baldwin/Schwartz- (Schwartz, 1994; Baldwin, 1997)	  and the Ballesteros/Weinstein-
numbering system (Ballesteros, 1995) is given in the tables.) Furthermore, the 2-Nal3 
side chain is located in a hydrophobic pocket facing TM-5, while D-Tyr5 is proposed 
to interact with either Glu32 in the N-terminus, Tyr45 in TM-1, or aromatic residues in 
ECL-2. Moreover, the chemokine-receptor conserved Glu288, a residue often involved 
in binding of positively charged small-molecule ligands (Rosenkilde, 2006), is 
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suggested to interact indirectly with FC131 via water molecules (Yoshikawa, 2012; 
Mungalpara, 2012). Thus, in line with reported SAR for FC131, the crucial Arg2 and 
2-Nal3 side chains bind deep in the receptor main binding crevice, while the less 
important Arg1 and D-Tyr5 side chains experience a larger degree of conformational 
flexibility and are partly solvent-exposed, facing the extracellular surface of the 
receptor (Mungalpara, 2013). However, none of these computational models has been 
accompanied by in vitro experiments that verify the suggested binding modes. 
To determine the binding mode for the lead cyclopentapeptide CXCR4 antagonist 
FC131, we here report experimental studies that involve modifications of both 
receptor and ligand. Thus, FC131 and the three analogues [Cit1]FC131 (substitution 
of the positively charged L-Arg in position 1 with the neutral L-citrulline), 
[Aib1]FC131 (substitution of Arg1 with the small hydrophobic 2-aminoisobutyric 
acid) and [D-Arg1]FC131 (opposite stereochemistry in position 1) (Figure 1B), were 
tested in a library of 25 CXCR4 mutations including Ala-, Asn- or Trp-substitutions 
of residues in TM-1 to -7 and ECL-2 (Figure 1C) in 125I-12G5-binding and receptor-
activation assays. This combined approach is the first of its kind to directly 
investigate the binding mode for FC131 in CXCR4 with in vitro experiments. 
Interestingly, the receptor-mutagenesis also revealed residues important for CXCL12-
induced receptor activation. The combined findings provide new experimental insight 
into the molecular mechanisms of CXCR4 antagonism and will facilitate future 
design of novel CXCR4 antagonists. 
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Methods 
 
Materials - All reagents and solvents were purchased and used as received without 
further purification. The human chemokine CXCL12 was purchased from Peprotech 
(NJ, USA). Human CXCR4 receptor cDNA was kindly provided by Timothy NC 
Wells (GSK, UK). [3H]-myo-Inositol (PT6-271), SPA beads and 125I-Bolton-Hunter 
reagent were purchased from Perkin Elmer (MA, USA). 12G5 antibody was kindly 
provided by Jim Hoxie (University of Pennsylvania, Philadelphia, PA, USA) and was 
iodinated in house as described previously (Rosenkilde, 2004). cDNA for the 
promiscuous chimeric G protein GΔ6qi4myr (abbreviated Gqi4myr) was kindly provided 
by Evi Kostenis (University of Bonn, Germany) (Kostenis, 1998). Primers for 
mutations were bought from TAG Copenhagen (Copenhagen, Denmark). The stock 
solution and dilutions of peptide antagonists were made in water. Stock solution and 
all dilutions of CXCL12 were made in buffer (1 mM acetic acid + 0.1% BSA). 
 
Compounds - Complete details of the synthesis and characterization of the 
cyclopentapeptide ligands FC131, [Cit1]FC131, [Aib1]FC131 and [D-Arg1]FC131 
have been reported earlier (Mungalpara, 2012). 
 
Site-directed mutagenesis - Receptor mutations were introduced by the polymerase 
chain reaction overlap extension technique or the QuikChange technique (Agilent 
Technologies, CA, USA) using WT CXCR4 as template. All reactions were carried 
out using Pfu polymerase (Stratagene, CA, USA) under conditions recommended by 
the manufacturer. The mutations were cloned into the eukaryotic expression vector 
pcDNA3.1+ (Invitrogen, UK) and verified by restriction endonuclease digestion and 
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DNA sequencing (Eurofins MWG Operon, Germany). 
 
Transfections and tissue culture - COS-7 cells were grown in Dulbecco's modified 
Eagle's medium (DMEM) with Glutamax (Invitrogen, UK) supplemented with 10% 
fetal bovine serum (FBS), 180 units/ml penicillin and 45 µg/ml streptomycin 
(PenStrep) at 37 °C in a 10% CO2/90% air-humidified atmosphere. Transfection of 
cells was carried out by the calcium phosphate precipitation method (Rosenkilde, 
1994; Kissow, 2012). Briefly, plasmid DNA (20 µg of receptor cDNA and 30 µg of 
the chimeric G protein Gαqi4myr for IP-assays or 40 µg receptor cDNA for 125I-12G5-
binding assays) were mixed with TE-buffer (10 mM Tris-HCl, 2 mM EDTA-Na2, pH 
7.5) and 30 µl calcium chloride (2 M) to a total volume of 480 µl, and was then added 
to the same amount of HEPES buffered saline (280 mM NaCl, 50 mM HEPES, 1.5 
mM Na2HPO4, pH 7.2). Precipitation was allowed for 45 min at room temperature, 
after which the precipitate together with 300 µl chloroquine (2 mg/ml) in 10 ml 
culture media was added to the 6 × 106 COS-7 cells seeded the day before. 
Transfection was stopped after 5 h by replacing media and cells were incubated 
overnight. 
 
Functional assay - The potency was measured using inositol-phosphate (IP) 
accumulation assays. In brief, one day after transfection COS-7 cells (1.5 × 105 
cells/well) were incubated for 24 h with 2 µCi of [3H]-myo-inositol in 0.3 ml of 
growth medium per well in a 24-well plate. The following day, cells were washed 
twice in PBS and were incubated in 0.2 ml of Hank's balanced salt solution 
(Invitrogen, U.K.) supplemented with 10 mM LiCl at 37 °C in the presence of various 
concentrations of ligands for 90 min. All mutations were tested for their ability to 
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become activated by CXCL12 using concentrations from 10 pM to 0.1 µM. The IC50 
of the antagonists were determined in cells activated by CXCL12 to approximately 
80% of CXCL12 Emax. The antagonists (in a range from 1 nM to 100 µM) were added 
10 min prior to addition of CXCL12, and co-incubated with CXCL12 for 90 min. 
Assay-medium was then removed, and cells were extracted by addition of 1 ml of 10 
mM formic acid to each well, followed by incubation on ice for 30-60 min. The 
generated [3H]inositol-phosphates were purified on an AG 1-X8 anion exchange 
resin. After addition of multipurpose liquid scintillation cocktail (Gold Star, Triskem-
International, France), radiation was counted in a Beckman Coulter counter LS6500. 
As an alternative assay measuring IP accumulation, the scintillation proximity assay 
(SPA)-IP was sometimes used. In brief, one day after transfection, COS-7 cells 
(35.000 cells/well) were incubated with [3H]myo-inositol (5 µl/ml, 2 µCi/ml) in 0.1 
ml of media overnight in a 96-well plate. The next day, cells were treated as 
mentioned above with volumes adjusted as follows: 100 µl of reaction solution with 
LiCl and 50 µl ice cold formic acid (10 mM, 50 µl/well). The [3H]inositol-phosphates 
in the formic acid cell lysates were thereafter quantified by Ysi-poly-D-Lys coated 
SPA beads. Briefly, 20 µl of cell extract was mixed with 80 µl of SPA bead 
suspension in H2O (12.5 µg/µl) to give a final volume of 100 µl in a PicoPlate-96 
white plate. Plates were sealed, agitated for at least 30 min and centrifuged (5 min, 
1500 rpm). SPA beads were allowed to settle and react with the extract for 8 h before 
radioactivity was determined using a Packard Top Count NXT™ scintillation counter 
(PerkinElmer, MA, USA). All determinations were made in duplicate. These overall 
readouts have earlier been used effectively for CXCR4 and other chemokine receptors 
and were found to give comparable results (Brandish, 2003; Thiele, 2012; 
Mungalpara, 2012).  
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Binding experiments - Cells were transfected as described above. The number of cells 
seeded per well was determined by the apparent receptor expression efficiency and 
was aimed at obtaining 5-10% specific binding of the added radioactive ligand. Two 
days after transfection, cells were assayed by competition binding for 3 h at 4 °C 
using 10-15 pM 125I-12G5 plus unlabelled ligand in 0.2 ml (in 24-well-plates, up to 
150.000 cells/well) or 0.1 ml (96-well plates, up to 35.000 cells/well) of 50 mM 
HEPES buffer, pH 7.4, supplemented with 1 mM CaCl2, 5 mM MgCl2, and 0.5% 
(w/v) bovine serum albumin in 24-well plates. The binding of 125I-12G5 was 
competed for with increasing concentrations of the unlabelled ligand ranging from 10 
pM to 100 nM (12G5) or from 1 nM to 100 µM (FC131, [Cit1]FC131, [Aib1]FC131 
or [D-Arg1]FC131). After incubation, cells were washed quickly two times in 4 °C 
binding buffer supplemented with 0.5 M NaCl. Cells were lysed by addition of 0.5 ml 
carbamide solution (18% acetic acid, 8 M urea, 2% v/v P-40) and radioactivity was 
counted in a WALLAC Wizard Gamma Counter. Nonspecific binding was 
determined in the presence of 0.1 µM unlabelled 12G5. Determinations were made in 
duplicate. 
 
Enzyme-linked immunosorbent assay (ELISA) - COS-7 cells were seeded in 96-well 
plates (6 × 103 cells/well) and transfected with 12.5 ng/well N-terminally FLAG-
tagged receptor DNA using lipofectamine transfection according to manufacturers 
instructions (Invitrogen, CA, USA). Two days after transfection, cells were washed in 
Tris-buffered saline (TBS; 0.05 M Tris Base, 0.9% NaCl, pH7.6), fixed in 3.7% 
formaldehyde for 15 min at room temperature, washed three times in TBS and 
incubated in TBS with 2% BSA for 30 min. The cells were then incubated for 2 h 
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with anti-FLAG M1-antibody (Sigma-Aldrich, MO, USA) at 2 µg/ml in TBS with 1 
mM CaCl2 and 1% BSA. After three washes with TBS supplemented with 1 mM 
CaCl2, the cells were incubated with goat anti-mouse HRP-conjugated antibody at 0.8 
µg/ml (Thermo Fisher Scientific, IL, USA) for 1 h. The immunoreactivity was 
revealed by addition of TMB Plus substrate (Kem-En-Tec, Taastrup, Denmark) after 
three additional washes, and the reaction was stopped with 0.2 M H2SO4. Absorbance 
was measured at 450 nm on a Wallac Envision 2104 Multilabel Reader (PerkinElmer, 
MA, USA). 
 
Molecular docking - Docking of the cyclopentapeptide ligands to the CXCR4 receptor 
was performed as described earlier (Mungalpara, 2012). Briefly, the X-ray structure 
of human CXCR4 (bound to CVX15, PDB code 3OE0) (Wu, 2010) was prepared 
with the Protein Preparation Wizard workflow (Schrödinger Suite 2011 Protein 
Preparation Wizard; Epik version 2.2, Schrödinger, LLC, New York, NY, 2011; 
Impact version 5.7, Schrödinger, LLC, New York, NY, 2011; Prime version 2.3, 
Schrödinger, LLC, New York, NY, 2011), and our previously reported bioactive 
backbone conformation for FC131 (Våbenø, 2006b) was used to build the structure of 
the cyclopentapeptide ligands. The ligands were docked using Schrödingers induced-
fit docking workflow (Schrödinger Suite 2012 Induced Fit Docking protocol; Glide 
version 5.8, Schrödinger, LLC, New York, NY, 2012; Prime version 3.1, 
Schrödinger, LLC, New York, NY, 2012), which takes the conformational flexibility 
of both ligand and receptor residues into account. Asp187 was used as centroid for the 
docking box (a cube with 26 Å length) and a H-bond constraint was applied to the 
carboxylate oxygen atoms of Asp171. As the side chain of Arg188 partly restricted 
access to Asp171, the “trim” option was used for Arg188, i.e. the side chain is replaced 
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with a methyl group (alanine) in the initial docking step and then placed back in the 
final redocking step. For all four ligands, 100 initial poses were generated, and the top 
10 optimized poses were retrieved. 
 
Data analysis and statistics - Statistical analyses were performed using the GraphPad 
Prism 5 software (GraphPad Software, San Diego, CA). The EC50 and IC50 values 
represent the mean of at least three independent experiments (except for [Cit1]FC131 
and [Aib1]FC131 in 125G-binding to Y116A) performed in duplicates (for exact 
number of experiments, see tables). In cases of incomplete sigmoidal curves (plateau 
not reached), the curves were extrapolated to baselines (see below) to predict an EC50 
or IC50. If this seemed unjustified, logEC50/IC50 values were indicated as >-4 or >-7 in 
the tables. P values were calculated using unpaired two-tailed t-test with 95% 
confidence intervals. Dose-response curves represent averaged, normalized curves. 
The normalizations were done as follows: (1) In the functional assay, cells were 
activated to approximately 80% by addition of an appropriate concentration of 
CXCL12 (see section on functional assay). This activation was set to 100% in each 
individual experiment, while the background-response observed for transfected cells 
in absence of ligand was set to 0%. The average of these normalized curves for each 
assay ("row means" in Prism 5) was then calculated. (2) In the 125I-12G5 binding 
assays, 100% equals maximum 125I-12G5 binding to receptor-expressing cells in the 
absence of unlabelled ligand, while 0% equals the unspecific binding observed with 
0.1 µM 12G5. 
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Results 
 
Expression	  and	  functionality of mutant receptors. 
A library of 25 CXCR4 mutations with Ala-, Asn- and steric hindrance substitutions 
of residues located in TM-1 to -7 and ECL-2 (Figure 1C) was created based on 
previously suggested binding modes of FC131 (Demmer, 2011; Yoshikawa, 2012; 
Mungalpara, 2012) and the ability of the residues to engage in H-bond, charge-charge, 
and hydrophobic interactions. Thus, these residues constituted likely interaction sites 
for the main functionalities of FC131, i.e. the positively charged side chains of Arg1 
and Arg2, the aromatic side chains of 2-Nal3 and D-Tyr5, and the peptide backbone.  
Initially, WT CXCR4 and all mutant receptors were tested for their surface expression 
using ELISA, and for their functional response towards the endogenous chemokine 
CXCL12 using COS-7 cells transiently transfected with receptor and the Gαi- to Gαq-
signal-converting chimeric Gα subunit Gqi4myr, thus measuring accumulation of 
intracellular inositol-phosphate (Table 1, Figure 1D). The majority of receptors 
displayed expression levels from 47-111% of WT. R183A, I259W and W94A ranged 
at the lower end of the scale with 18%, 34% and 39% of WT expression, respectively, 
while two receptors (R188A and H281A) showed expression levels higher than 130% 
compared to WT (Table 1). I259A and Q200A displayed the lowest expression with 
4.7% and 3.0% of WT-level; however, both receptors showed good responses towards 
CXCL12, demonstrating that they were functional and correctly folded. Likewise, the 
majority of the receptors showed good responses towards CXCL12 (Table 1, Figure 
1D). Only W94A, D97A and D187A resulted in 8.6- to 14-fold decreased potencies 
compared to WT CXCR4 and no response was observed for Y116A and E288A 
(discussed below), despite good surface expression (Table 1, Figure 1D).  
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Nine mutations were also assessed in 125I-12G5 competition binding experiments in 
transiently transfected COS-7 cells (Table 2). This assay has earlier been shown to 
correlate better with HIV-1 antiviral potency of CXCR4 antagonists than functional 
assays measuring CXCR4 signalling, and also displays a larger dynamic range 
(Gerlach, 2003; Rosenkilde, 2007). These selected receptors were able to bind 12G5 
with WT-like affinities (1.9 to 16 nM) (Table 2). The Bmax values were slightly, yet 
significantly, reduced for H113A, D171N, H281A and E288A (Table 2), which 
however did not correlate to their WT-like surface expression (Table 1). 
While secondary/global effects of the mutations on receptor structure and function 
cannot be excluded, the created set of receptor mutants was deemed suitable for 
mapping the binding site of FC131 by assessing its ability to inhibit CXCL12-
mediated activation or to displace 125I-12G5. 
 
FC131-mediated inhibition of CXCL12-induced receptor activation. 
The entire mutant library was tested in a functional assay determining the ability of 
the cyclopentapeptide antagonist FC131 to inhibit CXCL12-induced accumulation of 
intracellular inositol-phosphate. H113A, D171N and D262N in the major binding 
pocket resulted in 12- to 119-fold reduced FC131 potencies (Figure 2A), while no 
effects were observed for mutations in ECL-2 (D187A) and the top of TM-7 (H281A) 
(Figure 2B). Ala-substitution of TM-2 residues Trp94 and Asp97, pointing towards the 
minor binding pocket (defined by TM-1, -2, -3, -7), improved the potency of FC131 
(Figure 2C). CXCL12-induced activity was highly impaired in Y116A and E288A, 
both pointing into the major binding pocket (delimited by TM-3 to -7, Figure 1C), and 
FC131 was consequently not tested further here. A large number of mutations in TM-
3 (Thr117), ECL-2 (Arg183, Arg188, Phe189, and Tyr190), TM-5 (Val196, Phe199, Gln200, 
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and His203), TM-6 (Trp252, Tyr255, and Ile259), and TM-7 (Ile284) did not impair the 
antagonistic potency of FC131 (Table 1). However, a small decrease (4.1-fold) was 
observed for Ala-substitution of Tyr45 in TM-1. 
 
The binding site of FC131 is located in the major binding pocket of CXCR4. 
The impact of the nine selected mutations on the affinity of FC131 was assessed in 
the 125I-12G5 heterologous competition binding assay (Table 2). Here, similar results 
were obtained, yet with the expected generally larger changes in affinity (Table 2) as 
compared to changes in potency (Table 1). Thus, FC131 displayed high affinity to 
WT CXCR4 (IC50 of 0.74 µM), whereas the H113A, Y116A, D171N and D262N 
mutants resulted in 63- to >260-fold decreased affinities (Figure 2D). H281A and 
D187A resulted in a lower, though significant decrease (18- and 10-fold, 
respectively). A minor decrease in affinity was also observed for E288A (5.5-fold) 
(Figure 2E). Finally, in analogy to the functional assay results, W94A and D97A led 
to 25- and 4.6-fold increased affinities, respectively (Figure 2F). 
 
Molecular docking of FC131 in CXCR4. 
Next, FC131 was docked to the X-ray crystal structure of CXCR4 (PDB code 3OE0 
(Wu, 2010)) using the induced-fit docking protocol developed by Schrödinger (see 
Methods). As the binding and functional studies (Tables 1 and 2) both showed a 
dependence on the spatially close residues His113 (TM-3) and Asp171 (TM-4), a H-
bond constraint was set on the carboxylate group of Asp171. The following binding 
mode, which was among the top 10 optimized poses and supports the experimental 
data outlined above, is suggested (Figure 3A-C): Arg1 of FC131 interacts with Asp187, 
while Arg2 interacts with His113/Asp171; although also a direct interaction of Asp97 
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with Arg1 in FC131 is observed in this docking pose (not shown) and in earlier 
computational studies (Demmer, 2011; Yoshikawa, 2012; Mungalpara, 2012), the 
observation that the D97A mutation led to an increased affinity and potency of FC131 
argues for a different role of Asp97 (Figure 2C,F). The aromatic 2-Nal3 side chain is 
positioned in a tight hydrophobic pocket facing TM-5, and sandwiched between 
Arg188 (cation-π-interactions) and His203 (π-π-interactions). In most poses, D-Tyr5 of 
FC131 points towards Glu32 in the receptor N-terminus, while in some poses an 
interaction with Asp262 was observed (not shown). Finally, Glu288 interacts with the 
backbone of the ligand via a water-mediated hydrogen-bond network. Thus, FC131 
binds in the major binding pocket of CXCR4, with the Arg2 and 2-Nal3 side chains 
buried deeply, while the Arg1 and D-Tyr5 side chains point outward. 
Collectively, it was found that His113, Asp171, Asp187, and Glu288 are part of the 
binding site (Glu288 via water molecules), confirming recently suggested binding 
modes for FC131 (Demmer, 2011; Yoshikawa, 2012; Mungalpara, 2012), while 
Tyr45, Tyr116, and His281 are not directly interacting with FC131, but nevertheless 
influence its binding and activity to varying extents. A direct interaction of D-Tyr5 of 
FC131 with Asp262 is only seen in a few poses and is not likely to account for the 
large impact of the D262N mutation (96- and 12-fold decrease in affinity and 
potency, respectively, of FC131). However, Asp262 is a central residue in a H-bond 
network involving Gln200 (TM-5), His281 (TM-7) and Arg30 (N-terminus) (not shown) 
and removal of the charge in Asp262 may disturb this network and thereby indirectly 
affect FC131 binding and function. 
 
[Cit1]FC131 without a positively charged side chain in position 1 loses dependency 
on Asp187 in ECL-2. Previous SAR studies of FC131 (Figure 4A) have shown that 
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Arg1 (but not Arg2) can be replaced with the uncharged L-citrulline residue (Figure 
4B) (Mungalpara, 2012). In order to confirm the suggested binding mode of FC131 
(Figure 3), we subjected the [Cit1]FC131 analogue to the same mutational analysis in 
125I-12G5-binding and CXCL12-functional studies. Consistent with previous data 
(Mungalpara, 2012), [Cit1]FC131 displayed 6- to 8-fold lower affinity and potency as 
compared to FC131 (Tables 1 and 2). However, the effect of most mutations on 
[Cit1]FC131 was similar to that observed for FC131 (Figure 4D). Thus, mutation of 
residues facing the major binding pocket (H113A, Y116A, D171N, D262N) resulted 
in 9.6- to >20-fold decreases in affinity (Figure 4E and Table 2). H281A, in the top of 
TM-7, led to a 6.3-fold decrease, while E288A resulted in a partial displacement with 
unchanged affinity. Furthermore, as for FC131, mutations in TM-2 of the minor 
binding pocket (W94A and D97A) led to increased affinities (Table 2). However, 
contrary to what was observed for FC131 (Figure 4D), D187A in ECL-2 did not 
affect the binding of [Cit1]FC131 (Figure 4E). Thus, the affinity of FC131 on D187A 
(IC50 of 7.7 µM) is similar to the affinity of [Cit1]FC131 on WT CXCR4 (IC50 of 4.9 
µM), pointing towards an interaction of side chain 1 with Asp187.  
The effect of receptor mutants on the ability of [Cit1]FC131 to inhibit CXCL12-
mediated activation confirmed the picture observed in 125I-12G5-binding. Mutation of 
residues in the major binding pocket, including those located deeply and those located 
more superficially, resulted in strongly (H113A) or moderately (I284A, D171N) 
decreased, or unchanged (D262N, H281A) potency of [Cit1]FC131 (Table 1). The 
lack of effect for D262N could be due to the generally smaller dynamic window in 
functional studies compared to 125I-12G5-binding and the smaller effect observed in 
binding for [Cit1]FC131 (12-fold) vs. FC131 (96-fold). Furthermore, the potency of 
[Cit1]FC131 was decreased 5.7-fold for Y45A, while mutation of residues in TM-2 
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led to increased potencies (W94A, D97A) (Table 1). As expected from 125I-12G5-
binding experiments, D187A did not impair the antagonistic potency of [Cit1]FC131 
(Figure 4H). Analysis of neighbouring residues in ECL-2 (Figure 4G,H) revealed that 
Ala-substitution of Arg188 led to a 15-fold reduced potency of [Cit1]FC131 (Figure 
4H), while having no effect on FC131 (Figure 4G). None of the other aromatic 
residues in ECL-2 (Phe189, Tyr190) affected the potency of either [Cit1]FC131 or 
FC131 (Figure 4G,H). This highlights the impact of the cation-π-interaction between 
2-Nal3 and Arg188 in the absence of Arg1. Molecular docking of [Cit1]FC131 into 
CXCR4 also reveals that Asp187 is pointing away from side chain Cit1 (Figure 4K,L). 
Of the remaining mutations (Thr117, Val196, Phe199, Gln200, His203, Trp252, Tyr255, 
Ile259) only W252A lead to 4.3-fold impaired potency (Table 1).  
 
[Aib1]FC131, which lacks a side chain functionality in position 1, displays the same 
binding mode as FC131 and [Cit1]FC131. As described above, FC131 tolerates 
removal of the positive charge from the side chain in position 1. It also tolerates 
truncation of this side chain to the backbone stabilizing di-substituted residue Aib, i.e. 
[Aib1]FC131 (Figure 4C) (Mungalpara, 2012), which has the same affinity and 
potency as [Cit1]FC131 (Tables 1 and 2). The mutagenesis study of this compound in 
125I-12G5 binding revealed a stronger dependence on residues in the major binding 
pocket (H113, Y116, D171, D262, H281) than for [Cit1]FC131. However, in analogy 
with [Cit1]FC131, no impact was observed for D187A or E288A, while W94A and 
D97A led to similar increases in affinity (Table 2, Figure 4F). [Aib1]FC131 also 
mirrored [Cit1]FC131 in the functional studies, with a few exceptions (Table 1): 
compared to [Cit1]FC131 it showed decreased dependency on Asp171 and Arg188 in 
TM-IV and ECL-2, respectively. In contrast, it depended to a higher degree on His203, 
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as its potency was decreased 6.8-fold by H203A (Figure 4I), while that of 
[Cit1]FC131 was only impaired 2.3-fold (Figure 4H). Thus, the importance of Arg188 
and His203 in sandwiching the 2-Nal3 side chain, as discussed above, seems to swap 
from Arg188 for [Cit1]FC131 to His203 for [Aib1]FC131. Furthermore, Y45A resulted 
in 16-fold decreased potency of [Aib1]FC131, compared to the smaller impact of 5.7-
fold for [Cit1]FC131. Finally, computational modelling confirms a binding mode that 
overlaps with those of FC131 and [Cit1]FC131 for side chains L-Arg2, 2-Nal3, Gly4 
and D-Tyr5 (Figure 4K,L). This emphasizes that side chain 1 is not required for 
achieving this binding mode of cyclopentapeptides in CXCR4, yet plays a role for 
high potency and affinity, as described earlier (Tamamura, 2005a; Demmer, 2011; 
Mungalpara, 2012). 
 
The close analogue [D-Arg1]FC131 behaves differently than FC131 in its ability to 
displace 125I-12G5. [D-Arg1]FC131 differs from FC131 only in the stereochemistry in 
position 1 and displays similar potency and 2-fold higher affinity; however, this 
compound interacted differently with CXCR4. In 125I-12G5-binding experiments, a 
stronger dependency was observed on His113, Tyr116, Asp171, Asp187, Asp262, His281 
and Glu288 for [D-Arg1]FC131 than for FC131, while in functional assays both 
compounds behaved largely similar on all mutants (Figure 5A, Tables 1 and 2). 
Interestingly, [D-Arg1]FC131 acted differently on mutations in TM-2 than FC131; 
while W94A consistently lead to increased affinities and potencies, D97A abrogated 
the ability of [D-Arg1]FC131 to displace 125I-12G5, while it, as for FC131, increased 
its antagonistic potency (Figure 5B). Molecular docking of [D-Arg1]FC131 to 
CXCR4 revealed a larger flexibility of the exteriorly located part of the molecule as 
compared to FC131. While D-Arg1 still mainly interacted with Asp187, D-Tyr5 
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displayed a larger degree of conformational freedom and pointed everywhere from 
TM-2 and the N-terminus to TM-6 (Figure 5C); however, the crucial ligand side 
chains Arg2 and 2-Nal3 bound to His113/Asp171 and the hydrophobic pocket around 
TM-5 in the same way as in FC131.  
 
A H-bond between Tyr116 and Glu288 plays a role in the activation of CXCR4. In the 
crystal structure of the complex between CXCR4 and the peptide antagonist CVX15 
(Figure 6A) (Wu, 2010) and in our models of the receptor-bound cyclopentapeptide 
ligands (Figure 3C) a H-bond is observed between Tyr116 in TM-3 and Glu288 in TM-
7. In vitro experiments showed that Ala-substitution of Tyr116 or Glu288 abolished the 
agonistic action of CXCL12 (Figure 6B), despite surface expression levels of 69% 
and 77% of WT, respectively (Table 1). Both mutant receptors bound 125I-12G5 with 
WT-like affinities suggesting proper folding of the receptors (Figure 6C). 
Furthermore, all four cyclopentapeptide ligands were unable to displace 125I-12G5 
from Y116A-CXCR4, while only [D-Arg1]FC131 was affected by E288A (Figure 6D, 
Table 2). Although Tyr116 was not revealed as a direct interaction partner for the 
cyclopentapeptide ligands in the docking studies, these mutagenesis data point 
towards a role of Tyr116 for the ability of the ligands to displace 125I-12G5. 
Furthermore, the H-bond between Tyr116 and Glu288 seems crucial for the activation of 
CXCR4 by CXCL12. Further studies are needed to fully understand the functional 
importance of the link between Tyr116 and Glu288 in CXCR4.  
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Discussion and Conclusions 
 
We have used a dual approach combining receptor mutational analysis with ligand 
modifications to determine the binding mode of FC131 in CXCR4: Arg1, Arg2, 2-Nal3 
and D-Tyr5 of FC131 interact with ECL-2 (Asp187), TM-3/-4 (His113, Asp171), TM-5 
and the exterior receptor part (Glu32), respectively. The orientation of FC131 in the 
pocket was confirmed by [Cit1]FC131 and [Aib1]FC131 that both lack the positive 
charge at position 1 and at the same time do not depend on Asp187. Overall, our data 
are consistent with earlier proposed binding modes predicting Arg1 and D-Tyr5 to 
point outwards, while Arg2 and 2-Nal3 interact with residues deep in the major 
binding pocket (Figure 3) (Demmer, 2011; Yoshikawa, 2012; Mungalpara, 2013). 
 
Comparison of the binding modes of FC131, CVX15 and AMD-compounds. 
The recent crystal structure of CXCR4 with the small-molecule IT1t or the peptide 
CVX15 (Wu, 2010) gave first-hand insights into antagonist interaction with CXCR4. 
Surprisingly, IT1t interacted with residues Glu288, Asp187 and Asp97 in the minor 
binding pocket, while the peptide ligand CVX15, a 16-mer analogue of the 14-mer 
T140 that FC131 was developed from, was located in the major binding pocket and in 
extracellular receptor regions. Specifically, Arg1 of CVX15 interacted with Asp187, 
Arg2 with His113/Asp171, and Arg14 with Asp262 (Wu, 2010). We find that FC131 
mimics the binding of CVX15 as it interacts with Asp187 via Arg1, and His113/Asp171 
via Arg2. Thus, the two arginine residues in FC131 correspond to Arg1 and Arg2 of 
CVX15, and not to Arg2 and Arg14 as originally intended (Figure 7). Asp262 was not 
found to interact with Arg1 or Arg2 of FC131 in any docking pose. Alternatively, the 
impact of D262N might be attributed to a central role of this residue in a H-bond 
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network involving Arg30, Gln200 and His281, as mentioned above. Furthermore, a link 
between ECL-2 (carrying Asp187) and Asp262 is established via Gln200 in TM-5, which 
is directly linked to ECL-2. Removing a conformational constraint between Asp262 in 
TM-6 and Gln200 in TM-5 might therefore alter the position of ECL-2. Such a 
scenario would also explain the weakened effect of D262N on analogues [Cit1]FC131 
and [Aib1]FC131, lacking the positive charge at position 1 and dependency on Asp187 
in ECL-2. 
Finally, 2-Nal3 of FC131 and the corresponding 1-Nal3 of CVX15 bind in a 
hydrophobic sub-pocket at TM-5; however, as previously suggested by comparing 
SAR data for the cyclopentapeptides and the larger peptide antagonists, the naphthyl 
groups do not completely overlap (Mungalpara, 2013). Clearly, the 2-Nal3 side chain 
of FC131 goes deeper into the hydrophobic sub-pocket, and presumably contributes 
more to activity than the 1-Nal3 side chain of CVX15. The tyrosine residue in position 
5 of both ligands takes up different positions. While Tyr5 of CVX15 faces the upper 
part of the hydrophobic pocket around TM-5 (Wu, 2010), rotation of D-Tyr5 to Glu32 
(N-terminus) was observed in the FC131-CXCR4 complex, again in agreement with 
SAR studies on this position suggesting a solvent-exposed, freely rotatable position in 
CXCR4 (Mungalpara, 2013). 
The well-described non-peptide AMD-compound series (the bicyclam AMD3100, the 
monocyclam AMD3465 and the non-cyclam AMD11070) was earlier shown to 
depend on Asp262/Glu288 in TM-6/-7 on one side, and Asp171 in TM-4 on the opposite 
side of the major binding pocket (Gerlach, 2003; Rosenkilde, 2004; Rosenkilde, 
2007). Furthermore, mutation of residues in the minor binding pocket were found to 
impair their action and multiple binding modes were subsequently suggested 
(Gerlach, 2003; Rosenkilde, 2004; Hatse, 2005; Rosenkilde, 2007; Wong, 2008; 
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Gudmundsson, 2009a; Gudmundsson, 2009b; Catalano, 2010; Miller, 2010; Skerlj, 
2011). In the present study, FC131 was found to only indirectly interact with Glu288 
via a water-mediated H-bond network, and therefore behaves somewhat differently 
from these reference CXCR4 antagonists and from most other small-molecule 
antagonists where the chemokine-receptor conserved Glu in position VII:06/7.39 
seems to function as a general anchor point for positively charged nitrogens 
(Rosenkilde, 2006). 
 
The role of ECL-2 in the binding of cyclic pentapeptides in CXCR4. 
ECL-2 connects TM-4 with TM-5 and is covalently linked to the top of TM-3 via a 
conserved disulphide bond. Thereby, the C-terminal part of ECL-2 (also called ECL-
2b) is being held close to the extracellular surface of the main binding crevice of 
CXCR4. Asp187 is located in position Cys+1 in ECL-2b and the D187A mutation 
resulted in decreased affinities of FC131, but not [Cit1]FC131, pointing towards an 
interaction of Asp187 with Arg1 of the cyclopentapeptides. The adjacent Arg188 was 
earlier suggested to interact with the aromatic 2-Nal3 side chain of FC131 by 
engaging in a cation-π-interaction. This is also observed in our studies (Figure 4H), 
yet we do not see an effect of R188A on the potency of FC131, whereas the potency 
of [Cit1]FC131 decreases by 15-fold and that of [Aib1]FC131 by 3.5-fold (however, 
for [Aib1]FC131 a role of the second suggested interaction partner for 2-Nal3, His203 
in TM-V, becomes visible) (Table 1). Thus, Asp187 seems to be the most important 
residue for FC131 in ECL-2, yet in the absence of the interaction between Arg1 in 
FC131 and Asp187 (in [Cit1] and [Aib1]FC131), the impact of Arg188 becomes visible. 
Alternatively, Arg188 of CXCR4 and Arg1 of FC131 might repel each other. Thus, the 
R188A mutation would remove the favourable interaction with 2-Nal3, but also the 
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unfavourable electrostatic repulsion of Arg1, leading to a zero net effect of R188A on 
FC131. Importantly, a similar direct role of ECL-2b was found for the CCR5 
antagonist aplaviroc (Maeda, 2006; Thiele, 2011). In a broader perspective, binding of 
small-molecule compounds to extracellular chemokine receptor domains has the 
potential of overlapping with the binding sites of chemokines, which due to their large 
size interact with the exterior parts of their receptors (Allen, 2007; Scholten, 2012). 
Small-molecule antagonists, although by default considered allosteric, may therefore 
become partially overlapping, resulting in competitive behaviour. 
 
The role of Tyr116 for the function of CXCR4 antagonists. 
According to the two-step model of chemokine receptor activation, the interaction 
between CXCR4 and CXCL12 involves distinct receptor and chemokine domains in 
binding and activation (Crump, 1997; Gupta, 2001). In CXCR4, the initial high-
affinity binding is mainly mediated by sulpho-tyrosines in the receptor N-terminus 
that interact with positively charged residues of CXCL12. In a second step, N-
terminal CXCL12 residues interact with transmembrane receptor residues, and 
presumably also ECL-2 to induce receptor activation (Crump, 1997; Ludeman, 2013). 
In agreement with this model, and consistent with the data presented here, Ala 
substitution of transmembrane residues Asp97, Tyr116, Glu288 affect the signalling 
properties (Table 1, Figure 6), but not the binding, of CXCL12 (Rosenkilde, 2007; 
Wong, 2008). Thus, it can be speculated that the observed H-bond between Tyr116 and 
Glu288 (Wu, 2010) is crucial for CXCL12-mediated receptor activation. Furthermore, 
the function of all tested cyclopentapeptides depended on Tyr116 (Table 2, Figure 6D), 
probably via an indirect mechanism, as no direct interaction with the ligand was 
observed (Figure 3C). Interestingly, the function of AMD3100 and AMD3465 has 
	   25	  
also been shown to depend on Tyr116 (Wong, 2008); however, it remains to be 
determined whether this effect is direct or indirect. Finally, as described above, Glu288 
was found to be an indirect interaction partner for FC131, but mutation only resulted 
in minor effects for most cyclopentapeptide ligands, except binding of [D-
Arg1]FC131 (Table 2). Thus, the Tyr116-Glu288 H-bond at the bottom of the major 
binding pocket is central not only for the activation but also for the inhibition of 
CXCR4, and consequently for the activity states of CXCR4. 
 
The entrance to the binding crevice in CXCR4 is covered by H-bond and Cys-bridge.  
While mutations in TM-2 (W94A, D97N) impair the affinity of the AMD-compounds 
(Wong, 2008), we observed that W94A and D97A increased the potencies and 
affinities of the cyclopentapeptide antagonists. In the crystal structure of CXCR4, 
Asp97 forms a salt bridge with Arg183 in ECL-2, which together with the chemokine-
receptor conserved disulphide bridge between the N-terminus and top of TM-7 results 
in a partly covered major binding pocket (Wu, 2010). This is not seen in the newly 
released structure of CCR5, which lacks Asp97 (or an equivalent thereof) and has a 
more open entrance to its binding pocket (Tan, 2013). Although speculative, it could 
therefore be argued that breaking the Asp97/Arg183-salt bridge by Ala-substitution of 
Asp97 releases the closed extracellular conformation of CXCR4 and gives FC131 
easier access to its binding pocket. Mutation R183A does however not lead to 
increased potency of FC131 (Table 1); yet in the absence of the Arg183 side chain it 
can be speculated that another residue takes over its function in the salt bridge to 
Asp97; a H-bond is indeed observed between Asp97 and the backbone of Cys186. 
W94A may have a similar effect by providing more space for Asp97, thereby breaking 
the H-bond with Arg183, or simply by creating more room for the ligand. 
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In conclusion, by combining receptor mutagenesis with ligand modifications we 
determined the binding site of FC131 in CXCR4. In addition, our studies suggest a H-
bond in the center of the receptor between Tyr116 and Glu288 to be essential for the 
activation state of CXCR4. Finally, consistent with other studies of class A 7TM 
receptors, hereunder EBI2 (GPR183), CCR5, and CCR2, where a central role of the 
top of TM-2 is identified for the activity state (Alvarez Arias, 2003; Benned-Jensen, 
2008; Rosenkilde, 2010), a possible gating function of the top of TM-2 for the 
entrance into the main binding crevice of CXCR4 is suggested, implying that 
improved CXCR4 antagonists could be obtained by creating smaller molecules that 
can easily migrate into the main binding crevice of CXCR4.  
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Tables 
Table 1. Functional analysis of the interaction between CXCR4 WT and mutants 
with CXCL12, FC131 and analogues. PI turnover was measured in COS-7 cells co-
transfected with CXCR4 receptor constructs and the promiscuous G protein Gqi4myr. 
Residue positions are given according to the numbering systems of Baldwin/Schwartz 
and Ballesteros/Weinstein. The number of experiments is shown in parentheses, and 
Fmut indicates the fold-difference (ratio) between the potency on WT CXCR4 
compared to mutant CXCR4 with colour codes as follows: red > 50; orange > 15, 
yellow > 5, green < 0.2. # Mutant also tested in binding assay (Table 2). Significance: 
*** P<0.001, ** P<0.01, * P<0.05.  
 
Helix Position Mutation % ± SEM (n) EC50 ± SEM EC50 Fmut (n) EC50 ± SEM EC50 Fmut (n) EC50 ± SEM EC50 Fmut (n) EC50 ± SEM EC50 Fmut (n) EC50 ± SEM EC50 Fmut (n)
(nM) % of WT ± SEM (µM) (µM) (µM) (µM)
wt wt wt# 100 ± 0.0 (5) -8.8 ± 0.04 1.5 1.0 94 ± 1.3 (69) -6.4 ± 0.04 0.40 1.0 (31) -5.5 ± 0.11 3.0 1.0 (22) -5.5 ± 0.09 2.9 1.0 (24) -6.3 ± 0.09 0.52 1.0 (19)
TM-1 I:07/1.39 Y45A 90 ± 7.0 (3) -8.5 ± 0.20 3.4 2.3 ** 40 ± 5.5 (10) -5.8 ± 0.09 1.6 4.1 *** (6) -4.8 ± 0.12 17 5.7 ** (4) -4.3 ± 0.07 46 16 *** (3) -5.8 ± 0.10 1.6 3.0 * (4)
II:20/2.60 W94A# 38 ± 6.4 (3) -7.7 ± 0.10 18 13 *** 31 ± 11 (17) -8.0 ± 0.30 0.01 0.03 *** (8) -6.8 ± 0.41 0.17 0.06 *** (9) -7.7 ± 0.14 0.02 0.01 *** (3) -7.3 ± 0.67 0.05 0.09 ** (3)
II:23/2.63 D97A# 99 ± 6.3 (4) -7.7 ± 0.07 20 14 *** 34 ± 3.5 (10) -7.4 ± 0.09 0.04 0.11 *** (5) -6.4 ± 0.02 0.44 0.15 * (3) -6.5 ± 0.07 0.35 0.12 ** (3) -7.2 ± 0.05 0.06 0.12 ** (3)
III:05/3.29 H113A# 80 ± 9.0 (3) -9.1 ± 0.08 0.84 0.58 ** 83 ± 8.1 (21) -4.3 ± 0.10 48 119 *** (11) > -4 > 100 > 33 (10) > -4 > 100 > 35 (5) > -4 > 100 > 170 (3)
III:08/3.32 Y116A# 69 ± 12 (3) -0.8 ± 5.9 (1)
III:09/3.33 T117A 74 ± 5.5 (3) -8.8 ± 0.09 1.7 1.2 57 ± 13 (4) -6.9 ± 0.05 0.14 0.34 ** (3) -5.4 ± 0.10 4.2 1.4 (3) -6 ± 0.14 1.0 0.34 (3) -6.1 ± 0.12 0.74 1.4 (3)
TM-4 IV:20/4.60 D171N# 67 ± 11 (3) -8.5 ± 0.08 3.2 2.2 *** 38 ± 4.7 (25) -5.3 ± 0.12 4.6 12 *** (13) -4.6 ± 0.12 25 8.3 *** (12) -5.2 ± 0.18 6.2 2.2 (5) -4.5 ± 0.27 28 54 *** (4)
ECL-2/Cys-3 R183A 17 ± 1.8 (3) -10 ± 0.20 0.10 0.07 *** 24 ± 1.4 (3) -6.3 ± 0.18 0.49 1.2 (3)
ECL-2 / Cys+1 D187A# 49 ± 8.7 (4) -7.9 ± 0.06 13 8.6 *** 41 ± 5.2 (3) -6.9 ± 0.02 0.14 0.35 *** (3) -6.1 ± 0.03 0.76 0.25 (3) -6.3 ± 0.12 0.49 0.17 ** (3) -6.5 ± 0.15 0.35 0.66 (3)
ECL-2 / Cys+2 R188A 174 ± 21 (3) -9.3 ± 0.08 0.53 0.36 ** 44 ± 3.5 (4) -6.1 ± 0.17 0.72 1.8 (3) -4.4 ± 0.09 44 15 *** (3) -5.0 ± 0.25 10 3.5 (3) -5.7 ± 0.10 2.2 4.2 * (3)
ECL-2 / Cys+3 F189A 97 ± 8.7 (3) -8.7 ± 0.11 1.8 1.2 73 ± 9.5 (9) -7.0 ± 0.20 0.10 0.25 *** (6) -6.1 ± 0.19 0.79 0.27 * (5) -6.5 ± 0.30 0.31 0.11 *** (6) -6.8 ± 0.02 0.15 0.28 * (4)
ECL-2 / Cys+4 Y190A 105 ± 19 (3) -8.9 ± 0.18 1.2 0.82 69 ± 7.0 (8) -6.3 ± 0.24 0.47 1.2 (5) -5.6 ± 0.54 2.6 0.87 (4) -5.4 ± 0.13 4.0 1.4 (6) -6.2 ± 0.24 0.66 1.3 (3)
V:01/5.35 V196A 101 ± 13 (3) -8.9 ± 0.17 1.4 0.96 67 ± 15 (8) -6.3 ± 0.04 0.47 1.2 (4) -5.4 ± 0.22 3.6 1.2 (3) -5.3 ± 0.27 4.6 1.6 (3) -5.8 ± 0.27 1.6 3.0 (3)
V:04/5.38 F199A 79 ± 7.2 (3) -8.8 ± 0.06 1.4 0.98 76 ± 16 (4) -6.7 ± 0.11 0.21 0.52 * (4) -5.6 ± 0.17 2.3 0.77 (3) -5.5 ± 0.06 2.9 1.0 (3) -6.5 ± 0.16 0.31 0.59 (3)
V:05/5.39 Q200A 4.7 ± 2.8 (3) -8.9 ± 0.07 1.4 0.95 71 ± 5.1 (10) -6.4 ± 0.13 0.36 0.89 (5) -6.2 ± 0.12 0.61 0.20 * (3) -5.2 ± 0.19 6.9 2.4 (3) -6.2 ± 0.05 0.57 1.1 (3)
V:05/5.39 Q200W 75 ± 5.2 (3) -8.7 ± 0.08 1.8 1.2 34 ± 3.4 (11) -6.5 ± 0.19 0.33 0.83 (4) -5.6 ± 0.15 2.7 0.89 (3) -5.5 ± 0.16 2.8 1.0 (4) -6.1 ± 0.24 0.86 1.6 (3)
V:08/5.42 H203A 111 ± 4.6 (3) -8.9 ± 0.17 1.4 1.0 108 ± 24 (5) -6.2 ± 0.08 0.58 1.4 (3) -5.1 ± 0.24 8.0 2.7 (3) -4.7 ± 0.12 20 6.8 ** (3) -6.0 ± 0.15 0.98 1.9 (3)
VI:13/6.48 W252A 51 ± 4.3 (3) -9.1 ± 0.06 0.78 0.53 ** 75 ± 6.2 (11) -6.1 ± 0.11 0.71 1.8 * (5) -4.9 ± 0.19 13 4.3 * (5) -4.8 ± 0.18 16 5.8 ** (5) -5.5 ± 0.01 3.1 6.0 ** (3)
VI:16/6.51 Y255A 47 ± 3.5 (3) -8.9 ± 0.11 1.1 0.77 32 ± 9.7 (7) -6.6 ± 0.36 0.27 0.68 (5) -5.5 ± 0.24 3.2 1.1 (4) -5.1 ± 0.30 8.5 3.0 (3) -6.1 ± 0.55 0.8 1.6 (3)
VI:20/6.55 I259A 3.0 ± 0.3 (3) -8.7 ± 0.09 2.1 1.4 59 ± 4.6 (7) -7.1 ± 0.16 0.08 0.21 *** (5) -6.4 ± 0.49 0.41 0.14 * (3) -6.3 ± 0.32 0.53 0.18 * (3) -6.4 ± 0.53 0.4 0.84 (3)
VI:20/6.55 I259W 34 ± 4.3 (3) -8.9 ± 0.06 1.3 0.91 28 ± 4.2 (6) -6.8 ± 0.20 0.15 0.38 ** (5) -5.7 ± 0.23 2.2 0.74 (3) -6.2 ± 0.19 0.68 0.24 * (3) -6.2 ± 0.18 0.66 1.3 (3)
VI:23/6.58 D262N# 54 ± 4.1 (3) -8.2 ± 0.04 5.8 4.0 *** 63 ± 7.0 (23) -5.2 ± 0.09 6.1 15 *** (11) -5.3 ± 0.13 5.5 1.8 (12) -5.4 ± 0.13 4.3 1.5 (6) -5.0 ± 0.18 10 20 *** (4)
VII:-02/7.32 H281A# 169 ± 29 (3) -8.7 ± 0.13 1.8 1.2 33 ± 9.5 (18) -6.1 ± 0.19 0.80 2.0 * (12) -5.3 ± 0.17 5.2 1.7 (7) -6.4 ± 0.53 0.36 0.12 ** (4) -6.2 ± 0.29 0.60 1.1 (4)
VII:02/7.35 I284A 56 ± 9.7 (4) -8.6 ± 0.05 2.3 1.6 * 38 ± 4.3 (13) -6.6 ± 0.10 0.27 0.68 (5) -4.8 ± 0.42 15 4.9 * (3) -5.4 ± 0.13 3.8 1.3 (4) -5.6 ± 0.16 2.6 5.0 ** (4)
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Table 2. Affinity of 12G5, FC131, [Cit1]FC131, [Aib1]FC131 and [D-Arg1]FC131 
for WT CXCR4 and various CXCR4 mutations. The data were obtained from 
competition binding with 125I-labeled antibody 12G5 as radioligand on transiently 
transfected COS-7 cells. Values in parentheses represent number of experiments (n), 
and Fmut indicates the fold-difference (ratio) between the affinities on mutant receptor 
compared to WT receptor with colour codes as follows: red > 100 or no displacement 
at all, orange > 25, yellow > 5, green < 0.2. Significance: *** P<0.001, ** P<0.01, * 
P<0.05. Residue nomenclature is given as in Table 1. 
 
Helix Position Mutation IC50 ± SEM IC50 Fmut BMax ± SEM (n) IC50 ± SEM IC50 Fmut
(nM) (µM)
wt wt wt -8.3 ± 0.13 4.7 1.0 0.096 ± 0.018 (12) -6.1 ± 0.09 0.76 1.0
II:20/2.60 W94A -8.7 ± 0.15 1.9 0.40 0.053 ± 0.022 (8) -7.5 ± 0.07 0.03 0.04
II:23/2.63 D97A -8.0 ± 0.12 9.4 2.0 0.086 ± 0.013 (3) -6.8 ± 0.15 0.17 0.22
III:05/3.29 H113A -8.6 ± 0.15 2.7 0.6 0.037 ± 0.006 (7) * -4.3 ± 0.18 48 63
III:08/3.32 Y116A -8.1 ± 0.08 8.7 1.9 0.036 ± 0.016 (5) > -4 > 100 132
TM-4 IV:20/4.60 D171N -8.7 ± 0.18 2.2 0.47 0.034 ± 0.017 (7) * -4.3 ± 0.12 55 72
ECL-2 ECL-2 / Cys+1 D187A -7.8 ± 0.04 16 3.4 0.161 ± 0.012 (3) -5.1 ± 0.18 7.7 10
TM-6 VI:23/6.58 D262N -8.4 ± 0.15 3.7 0.8 0.101 ± 0.020 (8) -4.1 ± 0.18 73 96
VII:-02/7.32 H281A -8.6 ± 0.15 2.4 0.52 0.028 ± 0.008 (7) * -4.9 ± 0.11 13 18








P (n) IC50 ± SEM IC50 Fmut
(log) (µM)
(12) -5.3 ± 0.12 4.9 1.0
*** (9) -6.6 ± 0.16 0.27 0.06
** (3) -6.1 ± 0.05 0.87 0.18
*** (8) > -4 > 100 20
(3) > -4 > 100 20
*** (8) -4.3 ± 0.11 47 9.6
*** (3) -5.4 ± 0.20 4.3 0.87
*** (9) -4.2 ± 0.10 61 12
*** (8) -4.5 ± 0.17 31 6.3
*** (8) -5.7 ± 0.19 2.1 0.44
[Cit1]FC131
P (n) IC50 ± SEM IC50 Fmut
(log) (µM)
(11) !5.5 ± 0.16 2.9 1.0
*** (9) !6.9 ± 0.33 0.14 0.05
** (3) !5.9 ± 0.09 1.2 0.40
*** (8) No.displacement
*** (2) No.displacement
*** (8) >.!4 >.100 34
ns (3) !5.6 ± 0.19 2.6 0.9
*** (9) >.!4 >.100 34
*** (8) !4.0 ± 0.10 91 31
ns (6) !5.4 ± 0.10 4.2 1.4
[Aib1]FC131
P (n) IC50 ± SEM IC50 Fmut
(µM)
(5) -6.4 ± 0.14 0.38 1.0
** (3) -7.5 ± 0.09 0.03 0.08
ns (3) No displacement
(3) No displacement
(2) > -4 > 100 > 261
*** (3) > -4 > 100 > 261
ns (3) -4.9 ± 0.17 12 31
*** (3) > -4 > 100 > 261
*** (3) -4.0 ± 0.21 107 280
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Figure legends 
 
Figure 1. Compounds and mutations included in this study. (A) Structure of 
FC131 and (B) analogues [Cit1]FC131, [Aib1]FC131 and [D-Arg1]FC131, for which 
only the structure of the modified side chain 1 is shown. (C) Helical wheel diagram of 
CXCR4 as seen from the extracellular side showing the upper halves of the TMs and 
parts of ECL-2. Residues with black background are conserved among class A 
GPCRs and residues on grey background were mutated in this study. (D) Surface 
expression and response to 0.1 µM CXCL12 in functional assay of each mutant. 
 
Figure 2. Mutational analysis of FC131 in CXCL12-inhibition and 125I-12G5-
binding studies. The ability of FC131 to inhibit CXCL12-mediated activation (A-C) 
or to displace 125I-12G5 (D-F) from WT CXCR4 (stippled line) or mutants in the TM-
area (H113A, Y116A, D171N, D262N) (A, D), the exterior receptor parts (H281A, 
D187A) and E288A (B, E) or the minor binding pocket (W94A, D97A) (C, F) was 
assessed (see methods for details). H113A, white square; Y116A, black square; 
D171N, black circle; D262N, white circle; D187A, white triangle/tip up; H281A, 
white triangle/tip down, E288A, black triangle/tip down, W94A, black triangle/tip up; 
D97A, white diamond. Y116A and E288A were not activated by CXCL12 and could 
therefore not be assessed in functional studies of FC131 (A, B); n ≥ 3. 
 
Figure 3. The binding mode of FC131 in CXCR4. (A) 2D representation of the 
FC131 binding site in CXCR4. Residue colours: red, negative; purple, positive; cyan, 
polar; green, hydrophobic. Interactions: pink full and stippled arrows, H-bond with 
main and side-chain, respectively; green line, π-π stacking; red line, cation-π 
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interaction; grey cloud, solvent exposed atom. 3D model of FC131 binding in CXCR4 
as seen from top (B) or the side (C). TM-5 and -6 have been removed for clarity. 
 
Figure 4. [Cit1]FC131 and [Aib1]FC131 confirm the orientation of FC131 in 
CXCR4, and highlight the role of Arg188 and His203 for sandwiching the 2-Nal3 
side chain. The structures of the side chains in position 1 of FC131 (A), [Cit1]FC131 
(B), and [Aib1]FC131 (C) are given. (D-F) 125I-12G5 binding assays on WT CXCR4 
and mutant receptors (H113A, D171N and D187N, symbols as in Figure 2). (G-I) 
Impact of mutations D187A, R188A, F189A, Y190A (ECL-2) and H203A (TM-5) in 
binding (D187A) or functional assays (other mutants) shown as fold-decreases. (K, L) 
Molecular docking of the analogues. 
 
Figure 5. Mutational analysis and computational modelling of [D-Arg1]FC131 
binding in CXCR4. (A) Fold-decreases of FC131 (grey) and [D-Arg1]FC131 (white) 
affinity (upper diagram) and antagonistic potency (lower diagram) observed for a 
range of mutants in comparison to WT CXCR4. (B) The effect of D97A (triangle, tip 
down) in comparison to WT (circles, stippled line) on the affinity (upper part) and 
potency (lower part) of FC131 (grey) and [D-Arg1]FC131 (white). (C) Molecular 
docking of [D-Arg1]FC131 (white structures) showing multiple binding poses in 
overlay with the FC131 binding pose (green structure). 
 
Figure 6. Mutation of the H-bond forming residues Tyr116 and Glu288 abolished 
CXCL12-induced receptor activation. (A) Tyr116 and Glu288 form a H-bond in the 
crystal structure of CXCR4 (here bound to CVX15, PDB code 3OE0). (B) Ability of 
CXCL12 to activate WT CXCR4 (white circles) and mutants Y116A (white 
	   42	  
diamonds) and E288A (black diamonds). (C) Homologous 125I-12G5 competition 
binding experiments on WT, Y116A and E288A (symbols as in A) and the Bmax of 
12G5 in fmol/1 × 106 cells for each receptor (inset). (D) Ability of FC131 to displace 
125I-12G5 from WT, Y116A, and E288A (symbols as in A). 
 
Figure 7. The binding of FC131 compared to CVX15. Overlay of the binding 
modes for FC131 (green) identified in the present study and CVX15 (yellow) from 
the co-crystal structure of CXCR4 and CVX15 (PDB code: 3OE0). 
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